Re-establishing Responsiveness in a Case of Refractory Metastatic Rectal Cancer with a Personalized de novo Combination Regimen

Chirantan Bose, Pradip Devhare, Dadasaheb Akolkar, Darshana Patil, Vineet Datta, Ashwini Ghaisas, Revati Patil, Sanket Patil, Sachin Apurwa, Navin Srivastava, Raja Dhasarathan, Shabista Khan, Shankar Somashekar, Kiran Bendale, Jinumary John, Rahul Gosavi, Ajay Srinivasan, Rajan Datar

Abstract


Introduction: Encyclopedic Tumor Analysis (ETA) is multi-analyte, molecular and functional interrogation to identify latent vulnerabilities in solid tumors which can then be targeted in organ- and label-agnostic combination treatment regimens.

Case Presentation: We describe here a case of metastatic rectal cancer in a 61-year-old male who was progressed on all prior Standard of Care (SoC) treatment modalities including surgery, chemotherapy and radiotherapy. We addressed disease recurrence via personalized therapy guided by ETA which revealed characteristic molecular heterogeneity in primary and metastatic lesions in terms of single nucleotide variations (SNVs) and gene copy number variations (CNVs).  Notably, a novel TBL1XR1 (Exon1) – PIK3CA (Exon 2) gene fusion was identified in the tumor along with gene copy number gains in TERT, IGF-1R, MYC, FGFR1 and EGFR genes.

Conclusion: ETA based molecular analysis with synchronous in vitro chemo-sensitivity profiling strategy helped to define de novo combinatorial therapy regimen of targeted and cytotoxic drugs which countered disease progression at each instance and led to the durable regression of primary as well as metastatic lesions.


Keywords


Colorectal Cancer; TBL1XR1-PIK3CA; Abiraterone; Cetuximab; Everolimus

Full Text:

PDF

References


Xie Y, Chen Y, Fang J. Comprehensive review of targeted therapy for colorectal cancer. Sig Transduct Target Ther 5, 22 (2020) doi.org/10.1038/s41392-020-0116-z.

Van der Jeught K, Xu HC, Li YJ, et al. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018;24(34):3834-3848. doi: 10.3748/wjg.v24.i34.3834.

Sobani ZA, Sawant A, Jafri M, et al. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. World J Clin Oncol. 2016;7(5):340‐351. doi:10.5306/wjco.v7.i5.340

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1-10. doi: 10.1200/JCO.19.02105.

Albanese I, Scibetta AG, Migliavacca M, et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun. 2004;325(3):784-91. doi: 10.1016/j.bbrc.2004.10.111.

Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-422. doi: 10.1093/annonc/mdw235.

Nagarkar R, Patil D, Crook T, et al. Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial. Oncotarget. 2019 Sep 24;10(54):5605-5621. doi: 10.18632/oncotarget.27188.

Ranade A, Patil D, Bhatt A, et al. Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC. J Pers Med. 2019;9(3):34. doi: 10.3390/jpm9030034.

Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol. 2011; 125(1-2):23-31.

Bertorelle R, Rampazzo E, Pucciarelli S, et al. Telomeres, telomerase and colorectal cancer. World J Gastroenterol. 2014 ;20(8):1940-50. doi: 10.3748/wjg.v20.i8.1940.

Lee KS, Kwak Y, Nam KH, et al. c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer. PLoS ONE. 2015;10(10): e0139727. doi.org/10.1371/journal.pone.0139727

Kwak Y, Nam SK, Seo AN, et al. Fibroblast Growth Factor Receptor 1 Gene Copy Number and mRNA Expression in Primary Colorectal Cancer and Its Clinicopathologic Correlation. Pathobiology. 2015;82(2):76-83. doi: 10.1159/000398807.

Vigneri PG, Tirrò E, Pennisi MS, et al. The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy. Front Oncol. 2015 ;5:230. doi: 10.3389/fonc.2015.00230.

Stransky N, Cerami E, Schalm S, et al. The landscape of kinase fusions in cancer. Nat Commun. 2014 ;5:4846. doi: 10.1038/ncomms5846.

Reidy DL, Vakiani E, Fakih MG, et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol. 2010 ;28(27):4240-6. doi: 10.1200/JCO.2010.30.4154.

Van Cutsem E, Eng C, Nowara E, et al. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res. 2014 ;20(16):4240-50. doi: 10.1158/1078-0432.CCR-13-2752.

Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 ;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

Modest DP, Ricard I, Heinemann V, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol. 2016;27(9):1746-53. doi: 10.1093/annonc/mdw261.

Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials† Ann Oncol. 2017 ;28(8):1713-1729. doi: 10.1093/annonc/mdx175.

Sinicrope FA, Okamoto K, Kasi PM, Kawakami H. Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clin Gastroenterol Hepatol. 2016;14(5):651-8. doi:

1016/j.cgh.2016.02.008.

Moretto R, Cremolini C, Rossini D, et al. Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. Oncologist. 2016;21(8):988-94. doi: 10.1634/theoncologist.2016-0084.

Brulé SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015;51(11):1405-14. doi: 10.1016/j.ejca.2015.03.015.

Chen KH, Shao YY, Chen HM, et al. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC Cancer. 2016 ;16:327. doi: 10.1186/s12885-016-2358-2.


Refbacks

  • There are currently no refbacks.


AJCC-REP (ISSN 2572-5742)Copyright © 2012-2021. All rights reserved. Published by Ivy Union Publishing, 3204 Valley Rush Dr, Apex, North Carolina 27502, United States